Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy

Cells(2023)10.3390/cells12121574Source: DataRank Database

Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy is a research paper published in Cells (2023). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

ensembl refsnp igsr

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: goldTopics (30)IDs (PubMed, PMC)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Farida S. Akhtari ORCID,Adrian J. Green ORCID,Tammy M. Havener ORCID,Michael L. Sikes ORCID,Julia Quintanhila

Live enrichment

PubMed:37371044 PMC:PMC10297299

North Carolina Biotech Center Institutional

Grant: 2017-IDG-1025

North Carolina Biotech Center Institutional

Grant: 1UM2AI30836-01

North Carolina Biotech Center Institutional

Grant: P30 CA016086

National Institutes of Health

Grant: 3P30CA016086-42S2

Cancer Center Support Grant

National Institute of Environmental Health Sciences

goldLicense: cc-by

publisherhttps://www.mdpi.com/2073-4409/12/12/1574/pdf?version=1686117696

publisherhttps://www.mdpi.com/2073-4409/12/12/1574/pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10297299/pdf/cells-12-01574.pdf

repositoryhttps://doaj.org/article/fc45090c563c425fbc7ecb27e7e70be1

repositoryhttps://dx.doi.org/10.3390/cells12121574

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

HumansPrednisoloneAntineoplastic AgentsAntigens, CD20Antibodies, MonoclonalPharmacogenomic Testing

Keywords

Tgfb1Cd20 (Ms4a1)Mkl1 (Mrtfa)Obinutuzumab (Gazyva®)Ofatumumab (Arzerra®, Kesimpta®)Rituximab (Rituxan®)QH573-671MKL1 (MRTFA)PrednisoloneCD20 (MS4A1)Antibodies, Monoclonalrituximab (Rituxan®)Antineoplastic AgentsAntigens, CD20ArticlePharmacogenomic TestingTGFB1obinutuzumab (Gazyva®)Humansofatumumab (Arzerra®, Kesimpta®)Cytology

Sustainable Development Goals

SDG 3: 3. Good health

Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy

FAIR Checklist

Authors (11)

Funding (5 grants)

Open Access

Topics

Annotations (Europe PMC)